Generex Biotechnology extends scope of U.S. patent protection for vaccine technology
According to the company, potentiation of the therapeutic and prophylactic potency of vaccines using Ii-Key hybrids is a core component of Antigen Express technology. Ii-Key is a small fragment of the MHC class II associated invariant chain (Ii protein) that works by increasing the ability of specific antigens to stimulate T helper cells. Antigen Express has recently initiated a Phase II clinical trial designed to test the efficacy of one of its immunotherapeutic Ii-Key hybrid vaccines (AE37) in breast cancer. It has also initiated clinical trials on a synthetic avian influenza vaccine designed using the same principal.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.